New targeted meds for IBC?
Meet the Experts
Jennifer Griggs, M.D., M.P.H. is a medical oncologist specializing in the treatment of breast cancer, with a a special interest in cancer survivorship, patient-physician communication, and quality of care for women with breast cancer.
Question from Bks: What is new for IBC? Any new targeted drugs in the works?
- Answer —Jennifer Griggs, M.D., M.P.H.: It appears that survival in inflammatory breast cancer (IBC) may be improving with improvements in breast cancer chemotherapies. At the University of Michigan, we are developing a focused program on inflammatory breast cancer in order to push forward the field in this important type of breast cancer. It is that kind of concentrated effort that will lead to rapid advancements. At this point, we are not specifically choosing targeted therapies more often in this cancer, but as with the triple-negative breast cancers, we are consistently recommending that patients have the best possible multi-specialty care.
On Wednesday, December 19, 2007, our Ask-the-Expert Online Conference was called Updates from San Antonio 2007. Jennifer Griggs, M.D., M.P.H. answered your questions and shared the newest research presented at this year's San Antonio Breast Cancer Symposium.
The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.
An original video-on-demand educational initiative brought to you by Breastcancer.org and Comcast. Visit www.comcast.net/pinkribbon each week through the end of October for engaging, up-to-date videos and information about the fight to end breast cancer.